Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAP-MS: Biomarker-Guided Combination Therapies for Multiple Sclerosis
NCT03109288Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2017
- Primary completion
- Jan 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of cilostazol, folinic acid, pirfenidone, dantrolene, pioglitazone in multiple sclerosis (MS), sponsored by National Institute of Allergy and Infectious Diseases. Started Aug 2017; status: recruiting.
02
Drugs
cilostazolfolinic acidpirfenidonedantrolenepioglitazone
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03109288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109288.